Fecal BA is a cost-effective, accurate biomarker, and it is associated with obvious bowel dysfunction in IBS-D and IBS-C patients
That means looking beyond the number on the scale and monitoring how the body is actually functioning throughout the process
Many patients repeat treatment every 1 to 4 weeks based on their goals
Side Effects and Safety Considerations Common side effects of oral semaglutide include nausea, vomiting, diarrhea, and constipation, particularly during the dose-escalation phase when your body is adjusting to the medication
Cagrilintide is for research use only
While the world has focused on the battle between injectables and oral tablets, the "Mucosal Frontier" addresses the three biggest hurdles in peptide therapy: 1 Bioavailability: By utilizing a mucosal delivery platform, the drug avoids first-pass metabolism in the liver, potentially offering a more efficient way for the body to utilize the peptide compared to traditional oral versions